Ardakani 2020.
| Study name | The study of of escitalopram ʼs effectiveness on treatment of mild to moderate depressive disorder and improvement of quality of life in patients who are undergone coronary artery bypass graft surgery (CABG): a randomized double blind placebo controlled trial |
| Methods | RCT design: 2‐arm parallel‐group trial Total N randomised: 41 Length of follow‐up: end of treatment, 8 weeks Analysis: not specified |
| Participants | Location: Iran Number of study centres and setting: 1, Tehran Heart Center Hospital, Tehran, Iran CAD criteria: undergone coronary artery bypass graft surgery Depression criteria: BDI scores between 10 and 20, confirmed through clinical interview by a psychiatrist (ICD F32.8) Other entry criteria: 18 to 75 years of age Exclusion criteria: previous history of intolerance to SSRI, psychosis or dementia or cognitive impairment, severe liver disease, high risk of postoperative cardiac complications such as bleeding, participating in other trials, history of bipolar disorder, patients treated with escitalopram or another antidepressant during the previous month, recent alcohol and substance abuse, pregnancy and lactation |
| Interventions | Intervention: escitalopram 10 mg/d Control: placebo, not further specified Duration of treatment: 8 weeks |
| Outcomes | Primary: change in depressive symptoms as a result of intervention effects on BDI‐II, quality of life quantified with the 36‐Item Short Form Health Survey Secondary: checklist of drug side effects |
| Starting date | 22 November 2020 |
| Contact information | Dr Mohammad Reza khodaie Ardakani Razi Psychiatric Hospital, Shahre Rey, Tehran, Iran T: +98 21 3340 1604 E: kh.ardakani@uswr.ac.ir |
| Notes |